Mark Jeffrey DeLong
CIK 1856078 · Chief Business & Strat Officer · last filed 2026-05-14
Mark Jeffrey DeLong is a Chief Business & Strat Officer who has filed 42 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$4.6M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
42
-$4.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Business & Strat Officer | 0 | $41.03 | $0 | -$4.59M | 42 | 2026-05-14 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −185,969 | $0 | EDGAR |
| 2026-02-13 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −368 | -$8.2K | EDGAR |
| 2026-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +36,606 | $0 | EDGAR |
| 2026-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −3,371 | -$73.4K | EDGAR |
| 2026-01-21 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,334 | -$26.4K | EDGAR |
| 2026-01-15 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,780 | -$39.5K | EDGAR |
| 2025-06-11 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-12 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −363 | -$10.4K | EDGAR |
| 2025-01-30 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −365 | -$10.8K | EDGAR |
| 2025-01-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −1,396 | -$42.5K | EDGAR |